Merck KGaA Raises 2026 Outlook Amid Pending Bio-Techne Acquisition
Merck KGaA has raised its full-year guidance for the third time this year following strong Q3 2026 financial results. The German conglomerate's optimistic outlook is driven by robust performance across its business segments and the strategic momentum surrounding its pending $11.3 billion acquisition of U.S.-based life sciences company Bio-Techne. The acquisition is expected to significantly bolster Merck KGaA's position within the life sciences sector. As the deal nears completion, investors are closely monitoring how the integration will impact long-term growth trajectories and market share in the biotechnology tools and services space.
Topics: acquisition earnings report guidance raise